Non-Small Cell Lung Cancer – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Non-Small Cell Lung Cancer – Pipeline Review, H1 2017’, provides an overview of the Non-Small Cell Lung Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Non-Small Cell Lung Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Non-Small Cell Lung Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Non-Small Cell Lung Cancer

The report reviews pipeline therapeutics for Non-Small Cell Lung Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Non-Small Cell Lung Cancer therapeutics and enlists all their major and minor projects

The report assesses Non-Small Cell Lung Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Non-Small Cell Lung Cancer

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Non-Small Cell Lung Cancer

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Non-Small Cell Lung Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3-V Biosciences Inc

3SBio Inc

4SC AG

AbbVie Inc

Ability Pharmaceuticals SL

ACEA Biosciences Inc

Adamed Sp z oo

Adaptimmune Therapeutics Plc

Advantagene Inc

Advaxis Inc

Advenchen Laboratories LLC

Allist Shanghai Pharmaceutical Technology Co Ltd

Altimmune Inc

Altor BioScience Corp

Amgen Inc

Andarix Pharmaceuticals Inc

AndroScience Corp

Apexigen Inc

Aptose Biosciences Inc

Argos Therapeutics Inc

Ariad Pharmaceuticals Inc

ARMO Biosciences Inc

Arog Pharmaceuticals Inc

ArQule Inc

Array BioPharma Inc

Arrien Pharmaceuticals LLC

Asana BioSciences LLC

Astellas Pharma Inc

Asterias Biotherapeutics Inc

Astex Pharmaceuticals Inc

AstraZeneca Plc

Atreca Inc

Aurigene Discovery Technologies Ltd

Aurobindo Pharma Ltd

AVEO Pharmaceuticals Inc

Axelar AB

Basilea Pharmaceutica Ltd

Batu Biologics Inc

Bavarian Nordic A/S

Bayer AG

BeiGene (Beijing) Co Ltd

Beijing Hanmi Pharmaceutical Co Ltd

BerGenBio ASA

Beta Pharma Inc

Betta Pharmaceuticals Co Ltd

BeyondSpring Pharmaceuticals Inc

Bicycle Therapeutics Ltd

Bio-Path Holdings Inc

Biocad

BioCancell Ltd

Biocon Ltd

BioLineRx Ltd

Bionovis SA

Biothera Pharmaceutical Inc

Blueprint Medicines Corp

Boehringer Ingelheim GmbH

Boston Biomedical Inc

Bristol-Myers Squibb Company

Calithera Biosciences Inc

CanBas Co Ltd

Cantargia AB

Cascadian Therapeutics Inc

CASI Pharmaceuticals Inc

CBT Pharmaceuticals Inc

Celgene Corp

CellAct Pharma GmbH

Celldex Therapeutics Inc

Cellectar Biosciences Inc

Cellmid Ltd

Cellular Biomedicine Group Inc

Chipscreen Biosciences Ltd

Chugai Pharmaceutical Co Ltd

Cielo Therapeutics Inc

Cipla Ltd

Cleave Biosciences Inc

Coherus BioSciences Inc

Corcept Therapeutics Inc

Cortice Biosciences Inc

Corvus Pharmaceuticals Inc

Critical Outcome Technologies Inc

CSPC Pharmaceutical Group Limited

CytImmune Sciences Inc

CytomX Therapeutics Inc

Cytori Therapeutics Inc

CytRx Corp

DAE HWA Pharmaceutical Co Ltd

Daiichi Sankyo Company Ltd

DanDrit Biotech A/S

Debiopharm International SA

DEKK-TEC Inc

DelMar Pharmaceuticals Inc

Denovo Biopharma LLC

Domainex Ltd

Double Bond Pharmaceutical International AB

Dr. Reddy's Laboratories Ltd

Dynavax Technologies Corp

Eagle Pharmaceuticals Inc

Eisai Co Ltd

Eleison Pharmaceuticals LLC

Eli Lilly and Company

Endocyte Inc

EnGeneIC Ltd

EntreChem SL

Enumeral Biomedical Holdings Inc

EpiThany Inc

Etubics Corp

Eudendron Srl

Evotec AG

Exelixis Inc

F. Hoffmann-La Roche Ltd

FibroStatin SL

Five Prime Therapeutics Inc

Formosa Laboratories Inc

Fujifilm Corp

G&E Herbal Biotechnology Co Ltd

G1 Therapeutics Inc

Galectin Therapeutics Inc

Gene Techno Science Co Ltd

Genelux Corp

Genentech Inc

Genmab A/S

Genocea Biosciences Inc

Genor BioPharma Co Ltd

Genosco Inc

Genzyme Corp

Gilead Sciences Inc

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd

Globeimmune Inc

GlycaNova Norway AS

Glycotope GmbH

Golden Biotechnology Corp

Gradalis Inc

GreenPeptide Co Ltd

Griffith University

Grunenthal GmbH

Halozyme Therapeutics Inc

Hanmi Pharmaceuticals Co Ltd

Heat Biologics Inc

Helix BioPharma Corp

Hemispherx Biopharma Inc

Heptares Therapeutics Ltd

HitGen LTD

Horizon Pharma Plc

Humorigin Biotechnology Corp

Hutchison China MediTech Ltd

iCeutica Inc

Ideaya Biosciences Inc

Ignyta Inc

Immune Design Corp

Immune Pharmaceuticals Inc

ImmunGene Inc

Immunocore Ltd

ImmunoGen Inc

Immunomedics Inc

Incyte Corp

Infinity Pharmaceuticals Inc

Inflection Biosciences Ltd

Innovation Pharmaceuticals Inc

Innovent Biologics Inc

Inovio Pharmaceuticals Inc

Intas Pharmaceuticals Ltd

Invectys SA

Inventiva

IO Biotech ApS

Io Therapeutics Inc

Ionis Pharmaceuticals Inc

JHL Biotech Inc

Jiangsu Hansoh Pharmaceutical Group Co Ltd

Jiangsu Hengrui Medicine Co Ltd

Jiangsu Kanion Pharmaceutical Co Ltd

Johnson & Johnson

Jounce Therapeutics Inc

Juno Therapeutics Inc

Kadmon Corp LLC

Karyopharm Therapeutics Inc

Kite Pharma Inc

Komipharm International Co Ltd

Kura Oncology Inc

Kyowa Hakko Kirin Co Ltd

LATITUDE Pharmaceuticals Inc

Leap Therapeutics Inc

Les Laboratoires Servier SAS

Lion Biotechnologies Inc

Lipopharma Therapeutics SL

Loxo Oncology Inc

Mabion SA

MacroGenics Inc

Mallinckrodt Plc

Mebiopharm Co Ltd

MedImmune LLC

Merck & Co Inc

Merck KGaA

Merrimack Pharmaceuticals Inc

Mersana Therapeutics Inc

Merus NV

Microlin Bio Inc

Millennium Pharmaceuticals Inc

Mirati Therapeutics Inc

Molecular Partners AG

MolMed SpA

Morphotek Inc

Multimmune GmbH

Mycenax Biotech Inc

NanoCarrier Co Ltd

NantKwest Inc

Natco Pharma Ltd

Nektar Therapeutics

Neumedicines Inc

NewLink Genetics Corp

Northwest Biotherapeutics Inc

Novartis AG

Oncobiologics Inc

Oncogenex Pharmaceuticals Inc

Oncolys BioPharma Inc

Oncolytics Biotech Inc

OncoMed Pharmaceuticals Inc

Ono Pharmaceutical Co Ltd

Onxeo SA

Optimum Therapeutics LLC

Oribase Pharma

OSE Immunotherapeutics

Oxford BioTherapeutics Ltd

Peregrine Pharmaceuticals Inc

Pfizer Inc

Pharma Mar SA

Philogen SpA

Phosplatin Therapeutics LLC

Plexxikon Inc

Polaris Pharmaceuticals Inc

Provectus Biopharmaceuticals Inc

PsiOxus Therapeutics Ltd

Puma Biotechnology Inc

Purdue Pharma LP

Qilu Pharmaceutical Co Ltd

Qu Biologics Inc

Quintessence Biosciences Inc

Qurient Co Ltd

Rafael Pharmaceuticals Inc

Reata Pharmaceuticals Inc

Recombio SL

Regeneron Pharmaceuticals Inc

Rexahn Pharmaceuticals Inc

Rgenix Inc

Richter Gedeon Nyrt

Samyang Holdings Corp

Sanofi

Scancell Holdings Plc

SciClone Pharmaceuticals Inc

ScinoPharm Taiwan Ltd

Seattle Genetics Inc

Selvita SA

Shanghai Fosun Pharmaceutical (Group) Co Ltd

Shanghai Pharmaceutical Co Ltd

Shionogi & Co Ltd

Sierra Oncology Inc

Sigma-Tau SpA

SignPath Pharma Inc

Simcere Pharmaceutical Group

Sotio AS

Spotlight Innovation Inc

Starpharma Holdings Ltd

Sumitomo Dainippon Pharma Co Ltd

SuviCa Inc

Symic Biomedical Inc

Symphogen A/S

Synactix Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Synermore Biologics Co Ltd

Systimmune Inc

Taiho Pharmaceutical Co Ltd

Takara Bio Inc

Tasly Pharmaceutical Group Co Ltd

TC BioPharm Ltd

Teva Pharmaceutical Industries Ltd

Tocagen Inc

Tolero Pharmaceuticals Inc

TRACON Pharmaceuticals Inc

Transgene SA

Trovagene Inc

Tyme Technologies Inc

UbiVac LLC

Ultimovacs AS

United BioPharma Inc

Vaccinex Inc

VasGene Therapeutics Inc

Vault Pharma Inc

Vaxon Biotech

Verastem Inc

VG Life Sciences Inc

ViiV Healthcare Ltd

Viralytics Ltd

XBiotech Inc

XuanZhu Pharma Co Ltd

Yooyoung Pharm Co Ltd

Zensun (Shanghai) Sci & Tech Co Ltd

Zydus Cadila Healthcare Ltd

Zymeworks Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 13

Non-Small Cell Lung Cancer - Overview 14

Non-Small Cell Lung Cancer - Therapeutics Development 15

Non-Small Cell Lung Cancer - Therapeutics Assessment 84

Non-Small Cell Lung Cancer - Companies Involved in Therapeutics Development 118

Non-Small Cell Lung Cancer - Drug Profiles 278

Non-Small Cell Lung Cancer - Dormant Projects 2323

Non-Small Cell Lung Cancer - Discontinued Products 2343

Non-Small Cell Lung Cancer - Product Development Milestones 2351

Appendix 2369

List of Tables

List of Tables

Number of Products under Development for Non-Small Cell Lung Cancer, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..9), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..10), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..11), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..12), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..13), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..14), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..15), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..16), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..17), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..18), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..19), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Products under Development by Companies, H1 2017 (Contd..8), H1 2017

Products under Development by Companies, H1 2017 (Contd..9), H1 2017

Products under Development by Companies, H1 2017 (Contd..10), H1 2017

Products under Development by Companies, H1 2017 (Contd..11), H1 2017

Products under Development by Companies, H1 2017 (Contd..12), H1 2017

Products under Development by Companies, H1 2017 (Contd..13), H1 2017

Products under Development by Companies, H1 2017 (Contd..14), H1 2017

Products under Development by Companies, H1 2017 (Contd..15), H1 2017

Products under Development by Companies, H1 2017 (Contd..16), H1 2017

Products under Development by Companies, H1 2017 (Contd..17), H1 2017

Products under Development by Companies, H1 2017 (Contd..18), H1 2017

Products under Development by Companies, H1 2017 (Contd..19), H1 2017

Products under Development by Companies, H1 2017 (Contd..20), H1 2017

Products under Development by Companies, H1 2017 (Contd..21), H1 2017

Products under Development by Companies, H1 2017 (Contd..22), H1 2017

Products under Development by Companies, H1 2017 (Contd..23), H1 2017

Products under Development by Companies, H1 2017 (Contd..24), H1 2017

Products under Development by Companies, H1 2017 (Contd..25), H1 2017

Products under Development by Companies, H1 2017 (Contd..26), H1 2017

Products under Development by Companies, H1 2017 (Contd..27), H1 2017

Products under Development by Companies, H1 2017 (Contd..28), H1 2017

Products under Development by Companies, H1 2017 (Contd..29), H1 2017

Products under Development by Companies, H1 2017 (Contd..30), H1 2017

Products under Development by Companies, H1 2017 (Contd..31), H1 2017

Products under Development by Companies, H1 2017 (Contd..32), H1 2017

Products under Development by Companies, H1 2017 (Contd..33), H1 2017

Products under Development by Companies, H1 2017 (Contd..34), H1 2017

Products under Development by Companies, H1 2017 (Contd..35), H1 2017

Products under Development by Companies, H1 2017 (Contd..36), H1 2017

Products under Development by Companies, H1 2017 (Contd..37), H1 2017

Products under Development by Companies, H1 2017 (Contd..38), H1 2017

Products under Development by Universities/Institutes, H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..6), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..7), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..8), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..9), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..10), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..11), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..12), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..13), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..7), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..8), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..9), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..10), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..11), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..12), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..13), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Non-Small Cell Lung Cancer – Pipeline by 3-V Biosciences Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by 3SBio Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by 4SC AG, H1 2017

Non-Small Cell Lung Cancer – Pipeline by AbbVie Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Ability Pharmaceuticals SL, H1 2017

Non-Small Cell Lung Cancer – Pipeline by ACEA Biosciences Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Adamed Sp z oo, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Adaptimmune Therapeutics Plc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Advantagene Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Advaxis Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Advenchen Laboratories LLC, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Allist Shanghai Pharmaceutical Technology Co Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Altimmune Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Altor BioScience Corp, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Amgen Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Andarix Pharmaceuticals Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by AndroScience Corp, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Apexigen Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Aptose Biosciences Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Argos Therapeutics Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Ariad Pharmaceuticals Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by ARMO Biosciences Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Arog Pharmaceuticals Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by ArQule Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Array BioPharma Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Arrien Pharmaceuticals LLC, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Asana BioSciences LLC, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Astellas Pharma Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Asterias Biotherapeutics Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Astex Pharmaceuticals Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by AstraZeneca Plc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Atreca Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Aurigene Discovery Technologies Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Aurobindo Pharma Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by AVEO Pharmaceuticals Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Axelar AB, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Basilea Pharmaceutica Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Batu Biologics Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Bavarian Nordic A/S, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Bayer AG, H1 2017

Non-Small Cell Lung Cancer – Pipeline by BeiGene (Beijing) Co Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by BerGenBio ASA, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Beta Pharma Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Betta Pharmaceuticals Co Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by BeyondSpring Pharmaceuticals Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Bicycle Therapeutics Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Bio-Path Holdings Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Biocad, H1 2017

Non-Small Cell Lung Cancer – Pipeline by BioCancell Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Biocon Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by BioLineRx Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Bionovis SA, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Biothera Pharmaceutical Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Blueprint Medicines Corp, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Boehringer Ingelheim GmbH, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Boston Biomedical Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Bristol-Myers Squibb Company, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Calithera Biosciences Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by CanBas Co Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Cantargia AB, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Cascadian Therapeutics Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by CASI Pharmaceuticals Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by CBT Pharmaceuticals Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Celgene Corp, H1 2017

Non-Small Cell Lung Cancer – Pipeline by CellAct Pharma GmbH, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Celldex Therapeutics Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Cellectar Biosciences Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Cellmid Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Cellular Biomedicine Group Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Chipscreen Biosciences Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Chugai Pharmaceutical Co Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Cielo Therapeutics Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Cipla Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Cleave Biosciences Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Coherus BioSciences Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Corcept Therapeutics Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Cortice Biosciences Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Corvus Pharmaceuticals Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Critical Outcome Technologies Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by CSPC Pharmaceutical Group Limited, H1 2017

Non-Small Cell Lung Cancer – Pipeline by CytImmune Sciences Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by CytomX Therapeutics Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Cytori Therapeutics Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by CytRx Corp, H1 2017

Non-Small Cell Lung Cancer – Pipeline by DAE HWA Pharmaceutical Co Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Daiichi Sankyo Company Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by DanDrit Biotech A/S, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Debiopharm International SA, H1 2017

Non-Small Cell Lung Cancer – Pipeline by DEKK-TEC Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by DelMar Pharmaceuticals Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Denovo Biopharma LLC, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Domainex Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Double Bond Pharmaceutical International AB, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Dr. Reddy's Laboratories Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Dynavax Technologies Corp, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Eagle Pharmaceuticals Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Eisai Co Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Eleison Pharmaceuticals LLC, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Eli Lilly and Company, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Endocyte Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by EnGeneIC Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by EntreChem SL, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Enumeral Biomedical Holdings Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by EpiThany Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Etubics Corp, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Eudendron Srl, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Evotec AG, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Exelixis Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by FibroStatin SL, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Five Prime Therapeutics Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Formosa Laboratories Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Fujifilm Corp, H1 2017

Non-Small Cell Lung Cancer – Pipeline by G&E Herbal Biotechnology Co Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by G1 Therapeutics Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Galectin Therapeutics Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Gene Techno Science Co Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Genelux Corp, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Genentech Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Genmab A/S, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Genocea Biosciences Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Genor BioPharma Co Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Genosco Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Genzyme Corp, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Gilead Sciences Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by GlaxoSmithKline Plc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Glenmark Pharmaceuticals Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Globeimmune Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by GlycaNova Norway AS, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Glycotope GmbH, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Golden Biotechnology Corp, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Gradalis Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by GreenPeptide Co Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Griffith University, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Grunenthal GmbH, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Halozyme Therapeutics Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Heat Biologics Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Helix BioPharma Corp, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Hemispherx Biopharma Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Heptares Therapeutics Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by HitGen LTD, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Horizon Pharma Plc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Humorigin Biotechnology Corp, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Hutchison China MediTech Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by iCeutica Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Ideaya Biosciences Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Ignyta Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Immune Design Corp, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Immune Pharmaceuticals Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by ImmunGene Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Immunocore Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by ImmunoGen Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Immunomedics Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Incyte Corp, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Infinity Pharmaceuticals Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Inflection Biosciences Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Innovation Pharmaceuticals Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Innovent Biologics Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Inovio Pharmaceuticals Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Intas Pharmaceuticals Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Invectys SA, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Inventiva, H1 2017

Non-Small Cell Lung Cancer – Pipeline by IO Biotech ApS, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Io Therapeutics Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Ionis Pharmaceuticals Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by JHL Biotech Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Johnson & Johnson, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Jounce Therapeutics Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Juno Therapeutics Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Kadmon Corp LLC, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Karyopharm Therapeutics Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Kite Pharma Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Komipharm International Co Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Kura Oncology Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by LATITUDE Pharmaceuticals Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Leap Therapeutics Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Les Laboratoires Servier SAS, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Lion Biotechnologies Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Lipopharma Therapeutics SL, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Loxo Oncology Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Mabion SA, H1 2017

Non-Small Cell Lung Cancer – Pipeline by MacroGenics Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Mallinckrodt Plc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Mebiopharm Co Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by MedImmune LLC, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Merck & Co Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Merck KGaA, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Merrimack Pharmaceuticals Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Mersana Therapeutics Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Merus NV, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Microlin Bio Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Millennium Pharmaceuticals Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Mirati Therapeutics Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Molecular Partners AG, H1 2017

Non-Small Cell Lung Cancer – Pipeline by MolMed SpA, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Morphotek Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Multimmune GmbH, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Mycenax Biotech Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by NanoCarrier Co Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by NantKwest Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Natco Pharma Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Nektar Therapeutics, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Neumedicines Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by NewLink Genetics Corp, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Northwest Biotherapeutics Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Novartis AG, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Oncobiologics Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Oncogenex Pharmaceuticals Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Oncolys BioPharma Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Oncolytics Biotech Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by OncoMed Pharmaceuticals Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Ono Pharmaceutical Co Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Onxeo SA, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Optimum Therapeutics LLC, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Oribase Pharma, H1 2017

Non-Small Cell Lung Cancer – Pipeline by OSE Immunotherapeutics, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Oxford BioTherapeutics Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Peregrine Pharmaceuticals Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Pfizer Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Pharma Mar SA, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Philogen SpA, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Phosplatin Therapeutics LLC, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Plexxikon Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Polaris Pharmaceuticals Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Provectus Biopharmaceuticals Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by PsiOxus Therapeutics Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Puma Biotechnology Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Purdue Pharma LP, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Qilu Pharmaceutical Co Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Qu Biologics Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Quintessence Biosciences Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Qurient Co Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Rafael Pharmaceuticals Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Reata Pharmaceuticals Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Recombio SL, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Regeneron Pharmaceuticals Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Rexahn Pharmaceuticals Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Rgenix Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Richter Gedeon Nyrt, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Samyang Holdings Corp, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Sanofi, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Scancell Holdings Plc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by SciClone Pharmaceuticals Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by ScinoPharm Taiwan Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Seattle Genetics Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Selvita SA, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Shanghai Fosun Pharmaceutical (Group) Co Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Shanghai Pharmaceutical Co Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Shionogi & Co Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Sierra Oncology Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Sigma-Tau SpA, H1 2017

Non-Small Cell Lung Cancer – Pipeline by SignPath Pharma Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Simcere Pharmaceutical Group, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Sotio AS, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Spotlight Innovation Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Starpharma Holdings Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by SuviCa Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Symic Biomedical Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Symphogen A/S, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Synactix Pharmaceuticals Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Syndax Pharmaceuticals Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Synermore Biologics Co Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Systimmune Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Taiho Pharmaceutical Co Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Takara Bio Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Tasly Pharmaceutical Group Co Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by TC BioPharm Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Tocagen Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Tolero Pharmaceuticals Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by TRACON Pharmaceuticals Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Transgene SA, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Trovagene Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Tyme Technologies Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by UbiVac LLC, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Ultimovacs AS, H1 2017

Non-Small Cell Lung Cancer – Pipeline by United BioPharma Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Vaccinex Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by VasGene Therapeutics Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Vault Pharma Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Vaxon Biotech, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Verastem Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by VG Life Sciences Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by ViiV Healthcare Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Viralytics Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by XBiotech Inc, H1 2017

Non-Small Cell Lung Cancer – Pipeline by XuanZhu Pharma Co Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Yooyoung Pharm Co Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Zensun (Shanghai) Sci & Tech Co Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Zydus Cadila Healthcare Ltd, H1 2017

Non-Small Cell Lung Cancer – Pipeline by Zymeworks Inc, H1 2017

Non-Small Cell Lung Cancer – Dormant Projects, H1 2017

Non-Small Cell Lung Cancer – Dormant Projects, H1 2017 (Contd..1), H1 2017

Non-Small Cell Lung Cancer – Dormant Projects, H1 2017 (Contd..2), H1 2017

Non-Small Cell Lung Cancer – Dormant Projects, H1 2017 (Contd..3), H1 2017

Non-Small Cell Lung Cancer – Dormant Projects, H1 2017 (Contd..4), H1 2017

Non-Small Cell Lung Cancer – Dormant Projects, H1 2017 (Contd..5), H1 2017

Non-Small Cell Lung Cancer – Dormant Projects, H1 2017 (Contd..6), H1 2017

Non-Small Cell Lung Cancer – Dormant Projects, H1 2017 (Contd..7), H1 2017

Non-Small Cell Lung Cancer – Dormant Projects, H1 2017 (Contd..8), H1 2017

Non-Small Cell Lung Cancer – Dormant Projects, H1 2017 (Contd..9), H1 2017

Non-Small Cell Lung Cancer – Dormant Projects, H1 2017 (Contd..10), H1 2017

Non-Small Cell Lung Cancer – Dormant Projects, H1 2017 (Contd..11), H1 2017

Non-Small Cell Lung Cancer – Dormant Projects, H1 2017 (Contd..12), H1 2017

Non-Small Cell Lung Cancer – Dormant Projects, H1 2017 (Contd..13), H1 2017

Non-Small Cell Lung Cancer – Dormant Projects, H1 2017 (Contd..14), H1 2017

Non-Small Cell Lung Cancer – Dormant Projects, H1 2017 (Contd..15), H1 2017

Non-Small Cell Lung Cancer – Dormant Projects, H1 2017 (Contd..16), H1 2017

Non-Small Cell Lung Cancer – Dormant Projects, H1 2017 (Contd..17), H1 2017

Non-Small Cell Lung Cancer – Dormant Projects, H1 2017 (Contd..18), H1 2017

Non-Small Cell Lung Cancer – Dormant Projects, H1 2017 (Contd..19), H1 2017

Non-Small Cell Lung Cancer – Discontinued Products, H1 2017

Non-Small Cell Lung Cancer – Discontinued Products, H1 2017 (Contd..1), H1 2017

Non-Small Cell Lung Cancer – Discontinued Products, H1 2017 (Contd..2), H1 2017

Non-Small Cell Lung Cancer – Discontinued Products, H1 2017 (Contd..3), H1 2017

Non-Small Cell Lung Cancer – Discontinued Products, H1 2017 (Contd..4), H1 2017

Non-Small Cell Lung Cancer – Discontinued Products, H1 2017 (Contd..5), H1 2017

Non-Small Cell Lung Cancer – Discontinued Products, H1 2017 (Contd..6), H1 2017

Non-Small Cell Lung Cancer – Discontinued Products, H1 2017 (Contd..7), H1 2017

List of Figures

List of Figures

Number of Products under Development for Non-Small Cell Lung Cancer, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports